Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RP3 · 1 trial · 1 indication
Percentage of participants with DLTs
Percentage of participants with TEAEs
Percentage of participants with SAEs
Percentage of participants with TEAEs ≥ Grade 3
Percentage of participants experiencing events requiring withdrawal from treatment.
RP2D of RP3 based on the safety and response data collected during the dose escalation phase (Part 1)
| Arm | Type | Description |
|---|---|---|
| Dose escalation of RP3 - superficial and/or deep/visceral tumors | EXPERIMENTAL | Dose escalation of RP3 alone in 2 cohorts with intratumoral (IT) injections including use of imaging guided injection for deep tumors. |
| Dose combination of RP3 and anti-PD1 therapy - superficial and/or deep/visceral tumors | EXPERIMENTAL | Dose combination of RP3 and anti-PD1 therapy. IT injections of RP3 including use of imaging guided injection for deep tumors. |
| Seronegative cohort | EXPERIMENTAL | Doses of RP3 (IT) in HSV seronegative participants. |
| Name | Type | Description |
|---|---|---|
| RP3 | BIOLOGICAL | Genetically modified HSV-1 |
| Nivolumab | BIOLOGICAL | anti-PD1 monoclonal antibody |
Inclusion Criteria: * Patients with advanced or metastatic non-neurological solid tumors, who have progressed on standard therapy or cannot tolerate standard therapy, or for whom there is no standard therapy preferred to enrollment in a clinical study * All patients must consent to provide archival...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
RP3 is an investigational monoclonal antibody being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities. The drug is being evaluated as a potential therapy for patients with advanced solid tumors.
RP3 targets CD40L, 4-1BBL, and CTLA-4. These are molecular targets involved in immune system regulation. By targeting these molecules, RP3 is designed to modulate immune responses in the context of cancer treatment for advanced solid tumors.
RP3 is being developed by Replimune Group, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol REPL. Replimune is conducting clinical trials to evaluate RP3 as a potential treatment for advanced solid tumors.
RP3 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied in an active clinical trial for the treatment of advanced solid tumors.
RP3 is being studied in a Phase 1 clinical trial with the identifier NCT04735978. This trial is titled "Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours." The trial is active but not recruiting, with an enrollment of 123 participants.
RP3 is a distinct investigational drug being developed by Replimune Group, Inc. It is not known to be the same as any other approved or investigational drug. RP3 is being studied as a monotherapy and in combination with nivolumab for advanced solid tumors.